4736.Tw
4736.TW operates in the medical equipment, supplies, and distribution industry, generating revenue primarily through the sale of healthcare products and services.
Business. 4736.TW operates in the medical equipment, supplies, and distribution industry, generating revenue primarily through the sale of healthcare products and services.
Analyst recommendations
1 analysts · consensus HoldAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
4736.TW operates in the medical equipment, supplies, and distribution industry, generating revenue primarily through the sale of healthcare products and services.
The company maintains a strong capital structure with a debt-to-equity ratio of 0.12, indicating a conservative leverage position relative to its equity base. Its liquidity position is characterized by a current ratio of 3.18, suggesting the company has sufficient short-term assets to cover its short-term liabilities. However, the company's net cash position is negative after subtracting total debt, which raises some liquidity concerns.
In terms of profitability, the company demonstrates a return on equity (ROE) of 14.73% and a return on assets (ROA) of 11.28%, both of which are strong indicators of efficient capital use and asset management. These figures are well above the typical thresholds for the medical equipment and supplies industry, suggesting the company is outperforming its peers in generating returns.
The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. Geographically, the company's exposure is not explicitly detailed, but the absence of segmental or geographic diversification may pose a concentration risk. This lack of diversification could make the company more vulnerable to regional or sector-specific downturns.
Looking ahead, the company is expected to maintain a stable growth trajectory, with no significant changes in revenue or operating performance anticipated in the near term. The company's operating cash flow of 853,394,000 TWD and free cash flow of 425,196,000 TWD support this outlook, indicating the company has the financial flexibility to fund operations and potentially invest in growth opportunities.
The company faces moderate liquidity risk due to its negative net cash position after accounting for total debt. While the risk of dilution is currently low, the company's capital structure and financing activities should be monitored for any changes that could affect shareholder value. No recent events, such as filings or transcripts, have been disclosed that would significantly alter the company's risk profile.
No recent events, such as earnings calls, investor presentations, or regulatory filings, have been disclosed that would significantly alter the company's risk profile or strategic direction. The absence of such disclosures suggests the company is operating in a stable environment, with no immediate catalysts for change.
- The company maintains a conservative debt-to-equity ratio of 0.12, indicating a strong capital structure.
- Return on equity (14.73%) and return on assets (11.28%) are well above industry norms, suggesting strong profitability.
- The company's liquidity position is supported by a current ratio of 3.18, but its net cash position is negative after subtracting total debt.
- The company's revenue is concentrated in a single business segment, which may increase exposure to sector-specific risks.
- Analysts have issued a single "Hold" recommendation, with no strong buy or sell ratings, indicating a neutral outlook.
- No recent events have been disclosed that would significantly alter the company's risk profile or strategic direction.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 4736.TW Market data — financials · 2026-05-26
- Taidoc Technology Corp Market data — analyst estimates · 2026-05-26